Psychedelics & Emerging Therapies

There is a growing body of research into the therapeutic use of psilocybin, MDMA, and other psychedelics, and it is inspiring policymakers, medical experts, and the public to reexamine drug policy at every level of government. Vicente Sederberg is committed to working with communities to develop sensible policy solutions that advance the public interest.

Vicente Sederberg has specialized in cannabis policy for over a decade, and we understand the complexities of transitioning a controlled substance from a prohibition model to a more nuanced system, in which it is decriminalized or regulated for research and other legal purposes. Our attorneys have extensive experience shaping decriminalization and regulatory policies in the U.S. and internationally, helping businesses, governments, advocates, and others understand and tactically navigate the interplay between local, state, and federal laws.

Laws, legal authorities, and avenues for reform vary from city to city and state to state, so we help our clients craft and execute impactful strategies and policy reform movements tailored to the unique legal and political considerations that apply in each jurisdiction. We also maintain strategic relationships with firms that have extensive experience navigating the complex federal and state regulatory landscapes surrounding the development of novel and emerging therapeutic products. Most notably, VS has formed an alliance with Kleinfeld, Kaplan & Becker LLP, a Washington, D.C.-based firm that concentrates on the regulation of products subject to the jurisdiction of the U.S. Food and Drug Administration (FDA) — including drugs and biologics, medical devices, dietary supplements, and controlled substances — as well as advertising law and other regulatory law governing consumer products and services. See the "Services" tab below for more details.


Founding Partner


  • Assisting clients and advocacy organizations with the creation, drafting, and strategic implementation of local and state controlled substance policy reform measures

  • Assessing the risks for practitioners and other health care professionals in providing emerging therapies

  • Helping professional organizations shape ethical guidelines for practitioners in emerging therapies to set the standards for best practices

  • Providing corporate services for emerging therapies businesses, including forming benefit corporations

  • Protecting the religious freedoms and first amendment rights of organizations traditionally involved in entheogen practices

Through our alliance with Kleinfeld, Kaplan & Becker LLP, KKB attorneys can assist VS clients with:

  • Navigating the complex federal and state regulations applicable to researching, manufacturing, storing, importing, exporting, and marketing of controlled substances

  • Complying with the U.S. Food and Drug Administration’s ever-evolving and -technical requirements for developing, researching, manufacturing, obtaining regulatory approvals and clearances for, and marketing novel and emerging therapeutic products

  • Issues presented by developing professional licensure and scope-of-practice requirements applicable to researchers and healthcare providers working with novel and emerging therapeutic products


  • Assisted Decriminalize Denver with drafting and strategy for the successful 2019 Denver Psilocybin Initiative. The historic ballot measure designated possession of psilocybin mushrooms by persons 21 and older the city’s lowest law-enforcement priority, and it prohibited the city from spending resources to impose criminal penalties for such activities. 
  • Advised Decriminalize Nature on the Oakland Community Healing Initiative, including policy and legal considerations applicable to drafting a regulatory system that allows for legal access to entheogens. 
  • Advised the Heroic Hearts Project, a national nonprofit that connects military veterans struggling with mental trauma to ayahuasca therapy retreats.
  • Advised multiple clients engaging in legal entheogen-based therapy and related services, including drafting liability waivers and advising on corporate structure and procedure.
  • Advised a technology company on legal issues related to entheogen therapies.
  • Advised an entrepreneur regarding the legality of psilocybin production and research.
  • Advised multiple clients regarding biosynthetic cannabinoid production, including legal analyses with regard to the Controlled Substance Act, the Federal Analogue Act, and similar laws at the state level.
  • Advised a member of the Native American Church regarding unfair treatment by local law enforcement in connection with legal activities with entheogens. 


In the Media